Navigation Links
Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
Date:6/15/2008

SEATTLE, June 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced the Company has repaid the remaining balance, including accrued interest, of its 2008 Convertible Notes which reached maturity on June 15, 2008 through a cash payment of approximately $11.0 million. The Company currently has no debt maturing before Q3 2010.

"Retiring this last piece of current debt provides the Company more than 24 months to deliver our sales and product milestones before any additional convertible notes become due," said James A. Bianco, M.D., President and CEO of CTI.

The cash payment for the retirement of the 2008 Convertible Notes is the most recent step taken by the Company to improve its financial position including previously restructuring and retiring other convertible debt and preferred securities as well as recent financings that increased its cash position and institutional investor ownership.

This press-release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company continues to have negative cash flow and a significant amount of debt outstanding, redeemable preferred stock outstanding and will need to raise additional capital to fund its operations; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: media@ctiseattle.com

http://www.CellTherapeutics.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Ed Bell

T: 206.272.4345

F: 206.272.4434

E: invest@ctiseattle.com

http://www.CellTherapeutics.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
2. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
3. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
4. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
7. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
8. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
9. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
10. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
11. Cell Therapeutics, Inc. Announces Filing of Form 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... Feb. 16, 2017  Dermata Therapeutics, LLC, a ... treat a variety of dermatological diseases, today announced ... financing and entered into a $5 million credit ... to use the capital for general corporate purposes ... in the treatment of serious diseases treated by ...
Breaking Biology Technology:
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
Breaking Biology News(10 mins):